

ERRATA

New DNA enzyme targeting Egr-1 mRNA inhibits vascular smooth muscle proliferation and regrowth after injury

F.S. SANTIAGO, H.C. LOWE, M.M. KAVURMA, C.N. CHESTERMAN, A. BAKER, D.G. ATKINS & L.M. KHACHIGIAN

Nature Med. 5, 1264–1269 (1999).

On page 1264 in the paragraph beginning “To determine whether...”, the second and third sentences were incorrect. The corrected text is printed below.

ED5 cleaved this 23-nucleotide substrate (labeled with ^{32}P at the 5' end) within 10 minutes (Fig. 1*b*). The 12-nucleotide product (Fig. 1*b*) is consistent with the length between the A816–U817 junction and the 5' (radiolabeled) end of the substrate (Fig. 1*a*).

We regret this error.

Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2

A.GIROD, M. RIED, C. WOBUS, H. LAHM, K. LEIKE, J. KLEINSCHMIDT, G. DELÉAGE & M. HALLEK

Nature Med. 5, 1052–1056 (1999).

On page 1052, the last two column headings in Table 1 lacked the correct superscripting. The correct column headings are “particles/ml^a” and “A20+capsids/ml^b.” On page 1053, the column headings for Table 2 were shifted. The correct table is printed below.

We regret these errors.

Table 2 Infection of Co-115 and B16F10 cells

Virus	Titer on CO115 cells		Titer on B16F10 cells			
	heparin	RGDS	–	+	–	+
wt AAV2 ^a	–	–	–	–	–	–
I-447 ^a	–	–	–	–	–	–
I-587 ^a	–	–	–	–	–	–
rAAV/ <i>LacZ</i> ^b	–	–	–	–	–	–
rAAV(I-587)/ <i>LacZ</i> ^b	–	–	–	–	–	–

Titers of viral preparations are expressed ^ain Rep-EFU/ml for the viral preparations with the viral *rep* gene, or ^bin *LacZ*-EFU/ml for the viral preparations with the *LacZ* gene. Infection assays were done with (+) or without (–) heparin (100 µg/ml) or RGDS (200 µM) inhibitor. nd, not determined.